Ovarian NeoplasmsPhase 3NCT00102973
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
A Phase 3 study testing TLK286 in Combination with Carboplatin and Doxorubicin HCl Liposome Injection in people with Ovarian Neoplasms, run by Telik at 222 sites in United States.
Trial summary
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Neoplasms
- What is being tested?
- TLK286 in Combination with Carboplatin and Doxorubicin HCl Liposome Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 244 participants
- Where
- 222 sitesUnited States
- Study dates
- Dec 2004to Jul 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Are a woman 18 years of age or older
- Have histologically or cytologically confirmed epithelial cancer of the ovary or fallopian tube, or primary peritoneal cancer
- Have platinum refractory or resistant cancer
- Measurable disease according to radiographic RECIST criteria with documented tumor progression
Who cannot join
- Had treatment with first-line chemotherapy other than platinum-based regimens (carboplatin or cisplatin)
- Have clinically significant cardiac disease
- Have any sign of intestinal obstruction interfering with nutrition at the time of study entry
- Are pregnant or lactating
- Had prior treatment with liposomal doxorubicin for ovarian cancer
- Had prior treatment with TLK286
Trial locations and contacts
222 sites in 1 country.
222 sites in 1 country
United States222 sites
Western Washington Oncology, Inc., P.S.
Aberdeen, Washington, 98520
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Southern California Permanente Medical Group
Anaheim, California, 92807
East Bay Oncology/Hematology Medical Associates, Inc.
Antioch, California, 94509
Arlington Cancer Center
Arlington, Texas, 76012
Asheville Radiology
Asheville, North Carolina, 28801
Hope A Women's Cancer Center
Asheville, North Carolina, 28816
Southeastern Gynecologic Oncology
Atlanta, Georgia, 30342
Gynecologic Oncology & Minimally Invasive Surgery
Babylon, New York, 11702
Southern California Permanente Medical Group
Baldwin Park, California, 91706
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
The Family Cancer Center
Bartlett, Tennessee, 38133
Southern California Permanente Medical Group
Bellflower, California, 90706
Center for Cancer and Blood Disorders, P. C.
Bethesda, Maryland, 20817
Deaconess Billings Clinic
Billings, Montana, 59101
Cancer Care Center - Medcenter One, Inc.
Bismarck, North Dakota, 58501
Cancer Treatment & Research Center - Mid Dakota Clinic, P. C.
Bismarck, North Dakota, 58501
Odyssey Research
Bismarck, North Dakota, 58501
The Center for Hematology-Oncology
Boca Raton, Florida, 33486
Massachusetts General Hospital
Boston, Massachusetts, 02114
Dana Farber/Partners Cancer Care, Inc.
Boston, Massachusetts, 02115
Boston Medical Center - Center for Cancer and Blood Disorders
Boston, Massachusetts, 02118
Boston Medical Center
Boston, Massachusetts, 02118
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts, 02135
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Western Washington Oncology, Inc., P. S.
Centralia, Washington, 98531
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7570
Roper Hospital-Department of Radiology
Charleston, South Carolina, 29401
Carolina Center of Gynecologic Oncology, PA
Charleston, South Carolina, 29407
Carolinas Medical Center
Charlotte, North Carolina, 28203
Inpatient Pharmacy
Charlotte, North Carolina, 28203
Blumenthal Cancer Center
Charlotte, North Carolina, 28204
Presbyterian Gynecologic Oncology
Charlotte, North Carolina, 28204
Presbyterian Hospital
Charlotte, North Carolina, 28204
Baroness Erlander Hospital
Chattanooga, Tennessee, 37403
Chattanooga GYN Oncology
Chattanooga, Tennessee, 37403
Parkridge Medical Center
Chattanooga, Tennessee, 37404
Marshfield Clinic - Chippewa Falls Center
Chippewa Falls, Wisconsin, 54729
Marilyn Norton, M.D.
Chula Vista, California, 91911
Barrett Cancer Center
Cincinnati, Ohio, 45219-0501
UC Physician's Medical Arts Building
Cincinnati, Ohio, 45219
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
Fairview Hospital Moll Pavilion
Cleveland, Ohio, 44111
The Family Cancer Center
Collierville, Tennessee, 38017
Ellis Fischel Cancer Center
Columbia, Missouri, 65203
South Carolina Oncology
Columbia, South Carolina, 29210
Mid Ohio Onc/Hem (East)
Columbus, Ohio, 43213
GOPSA
Columbus, Ohio, 43222
Mid Ohio Onc/Hem (West)
Columbus, Ohio, 43222
Bay Area Cancer Research Group, LLC
Concord, California, 94520
East Bay Oncology/Hematology Medical Associates, Inc.
Concord, California, 94520
The Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Hematology and Oncology Specialists, LLC
Covington, Louisiana, 70433
Covington MultiCare - Oncology Clinic
Covington, Washington, 98042-4951
Citrus Diagnostic Center
Crystal River, Florida, 34428
Citrus Hematology and Oncology Center
Crystal River, Florida, 34428
Citrus Hematology and Oncology Center
Crystal River, Florida, 34429
Center for Oncology Research and Treatment, PA
Dallas, Texas, 75230
Texas Cancer Associates
Dallas, Texas, 75231
Danville Hematology and Oncology, Inc.
Danville, Virginia, 24541
Miami Valley Hospital
Dayton, Ohio, 45409
The Center for Hematology-Oncology
Delray Beach, Florida, 33484
Duluth Clinic
Duluth, Minnesota, 55805
Advance Imaging
Dunmore, Pennsylvania, 18512
Hematology & Oncology Associates of NEPA
Dunmore, Pennsylvania, 18512
Schwartz Gynecologic Oncology
East Islip, New York, 11730
Marshfield Clinic Cancer Care - Regional Cancer Center - Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
A. Richard Miskoff, DO, PA
Edison, New Jersey, 08818
JFK Medical Center
Edison, New Jersey, 08818
Elkhart General Hospital
Elkhart, Indiana, 46514
Southwest Cancer Care
Escondido, California, 92025
Dakota Cancer Institute
Fargo, North Dakota, 58103
Odyssey Research
Fargo, North Dakota, 58104
University of Connecticut Health Center/John Dempsey Hospital
Farmington, Connecticut, 06030
Joliet Oncology-Hematology Associates, Inc.
Flossmoor, Illinois, 60422
Southern California Permanente Medical Group
Fontana, California, 92335
California Oncology of the Central Valley
Fresno, California, 93710
Gig Harbor Medical Oncology
Gig Harbor, Washington, 98335
Greenville Hospital System
Greenville, South Carolina, 29605
Southern California Permanente Medical Group
Harbor City, California, 90710
Kaiser Permanente Medical Center
Hayward, California, 94545
GYN Oncology Associates, Inc.
Hollywood, Florida, 33021
Kaiser Permanente Hawaii
Honolulu, Hawaii, 96819
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
St. Vincent Hospital
Indianapolis, Indiana, 46260
Citrus Hematology and Oncology Center
Inverness, Florida, 34452
Citrus Memorial Hospital Radiology Dept.
Inverness, Florida, 34452
Florida Wellcare Alliance, LC
Inverness, Florida, 34452
Shands Jacksonville Medical Center
Jacksonville, Florida, 32209
Joliet Oncology-Hematology Associates, Inc.
Joliet, Illinois, 60432
Joliet Oncology-Hematology Associates, Inc.
Joliet, Illinois, 60435
Palm Beach Cancer Institute
Jupiter, Florida, 33458
Joliet Oncology-Hematology Associates, Inc.
Kankakee, Illinois, 60901
Gynecologic Oncology Associates
La Jolla, California, 92037
Cancer Center Oncology Medical Group
La Mesa, California, 91942
LaPorte Hospital
La Porte, Indiana, 46350
Western Washington Oncology, Inc., P.S.
Lacey, Washington, 98503
Sparrow Health System
Lansing, Michigan, 48912
Southeastern Gynecologic Oncology
Lawrenceville, Georgia, 30045
Mary Hitchcock Memorial Hospital/Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Cancer and Blood Disease Center
Lecanto, Florida, 34461
Little Rock Hematology Oncology
Little Rock, Arkansas, 72117
Arkansas Oncology Associates
Little Rock, Arkansas, 72205
Little Rock Hematology Oncology
Little Rock, Arkansas, 72205
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Arkansas Oncology Associates
Little Rock, Arkansas, 72207
LLU Faculty Medical Offices
Loma Linda, California, 92354
Loma Linda University Medical Center
Loma Linda, California, 92354
Southern California Permanente Medical Group
Los Angeles, California, 90027
Southern California Permanente Medical Group
Los Angeles, California, 90034
Bowyer Oncology Center
Los Angeles, California, 90095
David Geffen School of Medicine at UCLA
Los Angeles, California, 90095
OB/GYN Consult Suite
Los Angeles, California, 90095
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
University Medical Center, Inc. DBA: U of L Hospital
Louisville, Kentucky, 40202
North Shore University Hospital
Manhasset, New York, 11030
Southeastern Gynecologic Oncology
Marietta, Georgia, 30060
Marshfield Clinic
Marshfield, Wisconsin, 54449
Hillcrest Hospital/Cleveland Clinic Health System
Mayfield Heights, Ohio, 44124
The Family Cancer Center
Memphis, Tennessee, 38119
OncRx (Pharmacy)
Metairie, Louisiana, 70002
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Beverly Oncology and Imaging
Montebello, California, 90640
Clinical Trials and Research Associates, Inc.
Montebello, California, 90640
Oncology Care Medical Associates
Montebello, California, 90640
Joliet Oncology-Hematology Associates, Inc.
Morris, Illinois, 60450
Southwest Cancer Care
Murrieta, California, 92562
Jersey Shore University Medical Center
Neptune City, New Jersey, 07754
Robert Wood Johnson University Hospital
New Brunswick, New Jersey, 08901
The Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
Hematology-Oncology Associates of Rockland
New City, New York, 10956
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Hematology and Oncology Specialist
New Orleans, Louisiana, 70006
Newport Imaging Center
Newport Beach, California, 92660
Gynecologic Oncology Associates
Newport Beach, California, 92663
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663
Lakeland Hospital
Niles, Michigan, 49120
The Union State Bank Cancer Center
Nyack, New York, 10960
Kaiser Permanente Medical Center
Oakland, California, 94611
N. County Oncology Medical
Oceanside, California, 92056
The Family Cancer Center
Olive Branch, Mississippi, 38654
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Hematology & Oncology Consultants, PC
Omaha, Nebraska, 68122
Florida Hospital
Orlando, Florida, 32803
Gynecology Oncology
Orlando, Florida, 32804
Florida Hospital Memorial Division - Cancer Care Center
Ormond Beach, Florida, 32174
Florida Hospital Memorial System
Ormond Beach, Florida, 32174
Palm Beach Cancer Institute
Palm Beach Gardens, Florida, 33410
Southern California Permanente Medical Group
Panorama City, California, 91402
GYN Oncology Associates, Inc.
Pembroke Pines, Florida, 33028
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213
Texas Cancer Associates
Plano, Texas, 75093
Maine Medical Center - Brighton Campus
Portland, Maine, 04102
Maine Medical Center
Portland, Maine, 04102
Kaiser Permanente Northwest Region
Portland, Oregon, 97227
Oregon Health & Science University
Portland, Oregon, 97239
Southwest Cancer Care
Poway, California, 92064
Marshfield Clinic - Indianhead Center
Rice Lake, Wisconsin, 54868
Center for Oncology Research and Treatment, PA
Richardson, Texas, 75080
VCU Health System at Stony Point
Richmond, Virginia, 23235
VCU Health System-Dalton Oncology Clinic, North Hospital
Richmond, Virginia, 23298
Southeastern Gynecologic Oncology
Riverdale, Georgia, 30274
Southern California Permanente Medical Group
Riverside, California, 92505
Carilion GYN Oncology Associates
Roanoke, Virginia, 24014
Kaiser Permanente Medical Center
Sacramento, California, 95825
Lakeland Hospital
Saint Joseph, Michigan, 49085
Medical Oncology Associates
San Diego, California, 92123
Sharp Memorial Hospital - Investigational Pharmacy
San Diego, California, 92123
Sharp Rees-Stealy
San Diego, California, 92123
Kaiser Permanente Medical Center
San Francisco, California, 94115
Oncology Care Medical Associates
San Gabriel, California, 91776
Kaiser Permanente Medical Center
San Jose, California, 95119
Kaiser Permanente Medical Center
Santa Clara, California, 95051
Memorial Health University Medical Center
Savannah, Georgia, 31404
Maine Medical Center - Scarborough Campus
Scarborough, Maine, 04074
Horizons West Medical Group
Scottsbluff, Nebraska, 69361
Odyssey Research
Scottsbluff, Nebraska, 69361
Regional West Medical Center
Scottsbluff, Nebraska, 69361
The Women's Center of Western Nebraska
Scottsbluff, Nebraska, 69361
Hematology & Oncology Associates of NEPA
Scranton, Pennsylvania, 18508
Viewmont Medical Services
Scranton, Pennsylvania, 18508
Community Medical Center
Scranton, Pennsylvania, 18510
Mercy Health Partners
Scranton, Pennsylvania, 18510
Moses Taylor Hospital
Scranton, Pennsylvania, 18510
Western Washington Oncology, Inc., P.S.
Shelton, Washington, 98584
LSU Health Sciences Center
Shreveport, Louisiana, 71103
Sioux Valley Clinic - Clinical Research Center
Sioux Falls, South Dakota, 57104
Sioux Valley Clinic Oncology
Sioux Falls, South Dakota, 57104
Sioux Valley Hospital - North Center Radiology
Sioux Falls, South Dakota, 57104
Sioux Valley Clinic OBGYN, Ltd.
Sioux Falls, South Dakota, 57105
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Saint Joseph's Regional Medical Center
South Bend, Indiana, 46617
Kaiser Permanente Medical Center
South San Francisco, California, 94080
Providence Cancer Institute and Hospital
Southfield, Michigan, 48075
Spartanburg Regional Healthcare System
Spartanburg, South Carolina, 29303
Saint Louis University
St Louis, Missouri, 63117
St. John's Mercy Medical Center
St Louis, Missouri, 63141
St. John's Mercy-David C. Pratt Cancer Center
St Louis, Missouri, 63141
St. Michael's Hospital
Stevens Point, Wisconsin, 54481
Allenmore Hospital - Hematology Oncology Clinic
Tacoma, Washington, 98405
MultiCare Health System - Medical Oncology
Tacoma, Washington, 98405
Garth Phibbs, M.D., FACOG
Toledo, Ohio, 43606
ProMedica Health System
Toledo, Ohio, 43606
The Toledo Hospital
Toledo, Ohio, 43606
Southeastern Gynecologic Oncology
Tucker, Georgia, 30084
Cancer Care Associates
Tulsa, Oklahoma, 74104
Cancer Care Associates
Tulsa, Oklahoma, 74136
Associates in Hematology-Oncology, P.C.
Upland, Pennsylvania, 19013
Kaiser Permanente Medical Center
Vallejo, California, 94589
Kaiser Permanente Medical Center
Walnut Creek, California, 94596
Diablo Valley Oncology & Hematology Medical Group, Inc.
Walnut Creek, California, 94598
Perceptive Informatics, Inc.
Waltham, Massachusetts, 02451
Marchfield Clinic - Wausau Center
Wausau, Wisconsin, 54401
Palm Beach Cancer Institute
Wellington, Florida, 33414
Jsumc Ob/Gyn
West Long Branch, New Jersey, 07764
Palm Beach Cancer Institute
West Palm Beach, Florida, 33401
Mid Onio Onc/Hem (North)
Westerville, Ohio, 43081
Marshfield Clinic Weston Center
Weston, Wisconsin, 54476
Oncology Care Medical Associates
Whittier, California, 90602
Piedmont Hematology Oncology Associates
Winston-Salem, North Carolina, 27103
Marshfield Clinic - Wisconsin Rapids Center
Wisconsin Rapids, Wisconsin, 54494
Southern Permanente Medical Group
Woodland Hills, California, 91367
About this study
Official title: Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
- Conditions
- Ovarian Neoplasms
- Being tested
- TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection
- Keywords
- Ovary
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TLK286 in Combination with CarboplatinDrug
Experimental Arm
Doxorubicin HCl Liposome InjectionDrug
Active Comparator
| Study group | Role | What they receive |
|---|---|---|
| TLK286 in Combination with Carboplatin | Experimental | Not described Receives: Drug: TLK286 in Combination with Carboplatin |
| Doxorubisin HCl Liposome Injection | Active comparator | Not described Receives: Drug: Doxorubicin HCl Liposome Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study Objectives
To demonstrate superiority in the objective response rate (ORR) of TLK286 in combination with carboplatin as compared to active control therapy with liposomal doxorubicin
Measured: Every 8 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2005 (estimated)
- Study startDec 2004
- Primary completionJul 2008
- Study completionJul 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Ovarian NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 244 participants (actual)
Sponsor and investigators
- Lead sponsor
- Telik
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00102973
- Sponsor's protocol ID
- TLK286.3024
- Status last verified
- Jun 2006
- First submitted
- 4 Feb 2005
- Last updated
- 31 May 2012
- Results posted
- No
Publications
Newhouse R, Nelissen E, El-Shakankery KH, Rogozinska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3.
PubMed 37407274
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]
- ClinicalTrials.gov ID
- NCT00102973
- Acronym / sponsor ID
- TLK286.3024
- Conditions
- Ovarian Neoplasms
- Keywords
- Ovary
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 244 participants (actual)
- Lead sponsor
- TelikIndustry (pharma, biotech, devices)
- Study start
- Dec 2004
- Primary completion
- Jul 2008 (actual)
- Study completion
- Jul 2008 (actual)
- First posted
- 7 Feb 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TLK286 in Combination with Carboplatin | Experimental | Drug: TLK286 in Combination with Carboplatin |
| Doxorubisin HCl Liposome Injection | Active comparator | Drug: Doxorubicin HCl Liposome Injection |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Are a woman 18 years of age or older
- Have histologically or cytologically confirmed epithelial cancer of the ovary or fallopian tube, or primary peritoneal cancer
- Have platinum refractory or resistant cancer
- Measurable disease according to radiographic RECIST criteria with documented tumor progression
Key exclusion criteria (6 listed)
- Had treatment with first-line chemotherapy other than platinum-based regimens (carboplatin or cisplatin)
- Have clinically significant cardiac disease
- Have any sign of intestinal obstruction interfering with nutrition at the time of study entry
- Are pregnant or lactating
- Had prior treatment with liposomal doxorubicin for ovarian cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TLK286 in Combination with CarboplatinExperimental Arm | Drug | TLK286 in Combination with Carboplatin |
| Doxorubicin HCl Liposome InjectionActive Comparator | Drug | Doxorubisin HCl Liposome Injection |
Primary outcome
Study Objectives
Time frame: Every 8 Weeks
To demonstrate superiority in the objective response rate (ORR) of TLK286 in combination with carboplatin as compared to active control therapy with liposomal doxorubicin
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2012.
- Derived from this study: PubMed 37407274Newhouse R, Nelissen E, El-Shakankery KH, Rogozinska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3.
Related trials for Ovarian Neoplasms
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
222 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing TLK286 in Combination with Carboplatin and Doxorubicin HCl Liposome Injection in people with Ovarian Neoplasms, run by Telik at 222 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 May 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 222 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Study Objectives (time frame: Every 8 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00102973, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2012.